Header Logo

Doris M Benbrook

TitleProf
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentStephenson Cancer Center
AddressBRC 1217A
975 NE 10th St
Oklahoma City OK 73104
Phone405/271-5523
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    P50CA265793     (MUTCH, DAVID G)Aug 23, 2023 - Jul 31, 2028
    NIH
    Route 66 Endometrial Cancer SPORE
    Role: Co-Principal Investigator
    R01CA200126     (BENBROOK, DORIS MANGIARACINA)Jun 1, 2016 - May 31, 2022
    NIH
    Targeting HPV Consequences in a Cervical Cancer Clinical Trial
    Role: Principal Investigator
    R01CA196200     (BENBROOK, DORIS MANGIARACINA)Jul 1, 2015 - Jun 30, 2021
    NIH
    Ovarian Cancer Chemoprevention
    Role: Principal Investigator
    R01CA106713     (BENBROOK, DORIS MANGIARACINA)Jun 1, 2005 - Apr 30, 2011
    NIH
    Mechanism of SHeA2 Action in Ovarian Cancer
    Role: Principal Investigator
    R03CA099197     (BENBROOK, DORIS MANGIARACINA)Sep 30, 2003 - Aug 31, 2006
    NIH
    Steroids and Stem Cell in Carcinogenesis
    Role: Principal Investigator
    R01CA077711     (BENBROOK, DORIS MANGIARACINA)Jul 1, 1999 - Jun 30, 2004
    NIH
    MECHANISM &POTENTIAL OF RETINOID &DNA DAMAGE THERAPY
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Sharma A, Liu X, Chandra V, Rai R, Benbrook DM, Woo S. Pharmacodynamics of Cyclin D1 Degradation in Ovarian Cancer Xenografts with Repeated Oral SHetA2 Dosing. AAPS J. 2023 Dec 12; 26(1):5. PMID: 38087107.
      Citations:    Fields:    Translation:HumansAnimals
    2. Rai R, Lightfoot S, Benbrook DM. Manipulation of metabolic responses enhances SHetA2 efficacy without toxicity in cervical cancer cell lines and xenografts. Gynecol Oncol. 2023 Dec 04; 180:44-54. PMID: 38052108.
      Citations:    Fields:    Translation:HumansCells
    3. Rai R, Conrad R, Benbrook DM. Dataset on mucin 1 and 4 proteins and SialyT and T antigens staining patterns in cervical cancer primary tumors and metastatic lymph nodes. Data Brief. 2023 Jun; 48:109243. PMID: 37383750; PMCID: PMC10294000.
      Citations: 1     
    4. Rai R, Dey DK, Benbrook DM, Chandra V. Niclosamide causes lysosome-dependent cell death in endometrial cancer cells and tumors. Biomed Pharmacother. 2023 May; 161:114422. PMID: 36841028.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    5. Benbrook DM, Deng W, Gold MA, Rai R, Conrad R, van der Wel H, Husain S, Moore K, Spirtos N, Jackson AL, Zakhour M, Mathews CA, West CM. Association of Sialyl Tn antigen with cervical cancer lymph node status: An NRG oncology/GOG study. Gynecol Oncol. 2023 04; 171:67-75. PMID: 36827840; PMCID: PMC10040434.
      Citations: 2     Fields:    Translation:Humans
    6. Ade CJ, Dockery L, Walter AC, Benbrook DM, Vesely SK, Hammond ST, Moore KN, Holman LL. Association between Serum Biomarkers with Postoperative Complications and Delay of Adjuvant Chemotherapy Initiation in Ovarian Cancer Patients Undergoing Primary Cytoreductive Surgery: A Pilot Study. Nutr Cancer. 2023; 75(2):662-669. PMID: 36495155; PMCID: PMC10127353.
      Citations:    Fields:    Translation:Humans
    7. Rai R, Chandra V, Kennedy AL, Zuna RE, Benbrook DM. Distinct mechanism of cervical cancer cell death caused by the investigational new drug SHetA2. Front Oncol. 2022; 12:958536. PMID: 36203464; PMCID: PMC9531157.
      Citations: 1     
    8. Javadian P, Xu C, Sjoelund V, Borden LE, Garland J, Benbrook DM. Identification of Candidate Biomarker and Drug Targets for Improving Endometrial Cancer Racial Disparities. Int J Mol Sci. 2022 Jul 14; 23(14). PMID: 35887124.
      Citations: 2     Fields:    Translation:Humans
    9. Benbrook DM, Hocker JRS, Moxley KM, Hanas JS. Sera Protein Signatures of Endometrial Cancer Lymph Node Metastases. Int J Mol Sci. 2022 Mar 18; 23(6). PMID: 35328698.
      Citations: 2     Fields:    Translation:Humans
    10. Benbrook DM. SHetA2 Attack on Mortalin and Colleagues in Cancer Therapy and Prevention. Front Cell Dev Biol. 2022; 10:848682. PMID: 35281109.
      Citations: 3     
    11. Cybula M, Wang L, Wang L, Drumond-Bock AL, Moxley KM, Benbrook DM, Gunderson-Jackson C, Ruiz-Echevarria MJ, Bhattacharya R, Mukherjee P, Bieniasz M. Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research. Cancers (Basel). 2021 Dec 15; 13(24). PMID: 34944908.
      Citations: 10     
    12. Rai R, Kennedy AL, Isingizwe ZR, Javadian P, Benbrook DM. Similarities and Differences of Hsp70, hsc70, Grp78 and Mortalin as Cancer Biomarkers and Drug Targets. Cells. 2021 11 03; 10(11). PMID: 34831218.
      Citations: 11     Fields:    Translation:HumansAnimals
    13. Chandra V, Rai R, Benbrook DM. Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer. Cancers (Basel). 2021 May 12; 13(10). PMID: 34066052.
      Citations: 5     
    14. Javadian P, Washington C, Mukasa S, Benbrook DM. Histopathologic, Genetic and Molecular Characterization of Endometrial Cancer Racial Disparity. Cancers (Basel). 2021 Apr 15; 13(8). PMID: 33920951.
      Citations: 7     
    15. Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, Abeliovich H, Abildgaard MH, Abudu YP, Acevedo-Arozena A, Adamopoulos IE, Adeli K, Adolph TE, Adornetto A, Aflaki E, Agam G, Agarwal A, Aggarwal BB, Agnello M, Agostinis P, Agrewala JN, Agrotis A, Aguilar PV, Ahmad ST, Ahmed ZM, Ahumada-Castro U, Aits S, Aizawa S, Akkoc Y, Akoumianaki T, Akpinar HA, Al-Abd AM, Al-Akra L, Al-Gharaibeh A, Alaoui-Jamali MA, Alberti S, Alcocer-Gómez E, Alessandri C, Ali M, Alim Al-Bari MA, Aliwaini S, Alizadeh J, Almacellas E, Almasan A, Alonso A, Alonso GD, Altan-Bonnet N, Altieri DC, Álvarez ÉMC, Alves S, Alves da Costa C, Alzaharna MM, Amadio M, Amantini C, Amaral C, Ambrosio S, Amer AO, Ammanathan V, An Z, Andersen SU, Andrabi SA, Andrade-Silva M, Andres AM, Angelini S, Ann D, Anozie UC, Ansari MY, Antas P, Antebi A, Antón Z, Anwar T, Apetoh L, Apostolova N, Araki T, Araki Y, Arasaki K, Araújo WL, Araya J, Arden C, Arévalo MA, Arguelles S, Arias E, Arikkath J, Arimoto H, Ariosa AR, Armstrong-James D, Arnauné-Pelloquin L, Aroca A, Arroyo DS, Arsov I, Artero R, Asaro DML, Aschner M, Ashrafizadeh M, Ashur-Fabian O, Atanasov AG, Au AK, Auberger P, Auner HW, Aurelian L, Autelli R, Avagliano L, Ávalos Y, Aveic S, Aveleira CA, Avin-Wittenberg T, Aydin Y, Ayton S, Ayyadevara S, Azzopardi M, Baba M, Backer JM, Backues SK, Bae DH, Bae ON, Bae SH, Baehrecke EH, Baek A, Baek SH, Baek SH, Bagetta G, Bagniewska-Zadworna A, Bai H, Bai J, Bai X, Bai Y, Bairagi N, Baksi S, Balbi T, Baldari CT, Balduini W, Ballabio A, Ballester M, Balazadeh S, Balzan R, Bandopadhyay R, Banerjee S, Banerjee S, Bánréti Á, Bao Y, Baptista MS, Baracca A, Barbati C, Bargiela A, Barilà D, Barlow PG, Barmada SJ, Barreiro E, Barreto GE, Bartek J, Bartel B, Bartolome A, Barve GR, Basagoudanavar SH, Bassham DC, Bast RC, Basu A, Batoko H, Batten I, Baulieu EE, Baumgarner BL, Bayry J, Beale R, Beau I, Beaumatin F, Bechara LRG, Beck GR, Beers MF, Begun J, Behrends C, Behrens GMN, Bei R, Bejarano E, Bel S, Behl C, Belaid A, Belgareh-Touzé N, Bellarosa C, Belleudi F, Belló Pérez M, Bello-Morales R, Beltran JSO, Beltran S, Benbrook DM, Bendorius M, Benitez BA, Benito-Cuesta I, Bensalem J, Berchtold MW, Berezowska S, Bergamaschi D, Bergami M, Bergmann A, Berliocchi L, Berlioz-Torrent C, Bernard A, Berthoux L, Besirli CG, Besteiro S, Betin VM, Beyaert R, Bezbradica JS, Bhaskar K, Bhatia-Kissova I, Bhattacharya R, Bhattacharya S, Bhattacharyya S, Bhuiyan MS, Bhutia SK, Bi L, Bi X, Biden TJ, Bijian K, Billes VA, Binart N, Bincoletto C, Birgisdottir AB, Bjorkoy G, Blanco G, Blas-Garcia A, Blasiak J, Blomgran R, Blomgren K, Blum JS, Boada-Romero E, Boban M, Boesze-Battaglia K, Boeuf P, Boland B, Bomont P, Bonaldo P, Bonam SR, Bonfili L, Bonifacino JS, Boone BA, Bootman MD, Bordi M, Borner C, Bornhauser BC, Borthakur G, Bosch J, Bose S, Botana LM, Botas J, Boulanger CM, Boulton ME, Bourdenx M, Bourgeois B, Bourke NM, Bousquet G, Boya P, Bozhkov PV, Bozi LHM, Bozkurt TO, Brackney DE, Brandts CH, Braun RJ, Braus GH, Bravo-Sagua R, Bravo-San Pedro JM, Brest P, Bringer MA, Briones-Herrera A, Broaddus VC, Brodersen P, Brodsky JL, Brody SL, Bronson PG, Bronstein JM, Brown CN, Brown RE, Brum PC, Brumell JH, Brunetti-Pierri N, Bruno D, Bryson-Richardson RJ, Bucci C, Buchrieser C, Bueno M, Buitrago-Molina LE, Buraschi S, Buch S, Buchan JR, Buckingham EM, Budak H, Budini M, Bultynck G, Burada F, Burgoyne JR, Burón MI, Bustos V, Büttner S, Butturini E, Byrd A, Cabas I, Cabrera-Benitez S, Cadwell K, Cai J, Cai L, Cai Q, Cairó M, Calbet JA, Caldwell GA, Caldwell KA, Call JA, Calvani R, Calvo AC, Calvo-Rubio Barrera M, Camara NO, Camonis JH, Camougrand N, Campanella M, Campbell EM, Campbell-Valois FX, Campello S, Campesi I, Campos JC, Camuzard O, Cancino J, Candido de Almeida D, Canesi L, Caniggia I, Canonico B, Cantí C, Cao B, Caraglia M, Caramés B, Carchman EH, Cardenal-Muñoz E, Cardenas C, Cardenas L, Cardoso SM, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1. Autophagy. 2021 Jan; 17(1):1-382. PMID: 33634751.
      Citations: 840     Fields:    Translation:HumansAnimalsCells
    16. Elayapillai S, Ramraj S, Benbrook DM, Bieniasz M, Wang L, Pathuri G, Isingizwe ZR, Kennedy AL, Zhao YD, Lightfoot S, Hunsucker LA, Gunderson CC. Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. Gynecol Oncol. 2021 01; 160(1):302-311. PMID: 33131904.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    17. Leslie KK, Thiel KW, Benbrook DM, Mutch D. The Dawning of the Age of Personalized Medicine in Gynecologic Oncology. Cancers (Basel). 2020 Oct 27; 12(11). PMID: 33120871.
      Citations: 1     
    18. Kennedy AL, Rai R, Isingizwe ZR, Zhao YD, Lightfoot SA, Benbrook DM. Complementary Targeting of Rb Phosphorylation and Growth in Cervical Cancer Cell Cultures and a Xenograft Mouse Model by SHetA2 and Palbociclib. Cancers (Basel). 2020 May 17; 12(5). PMID: 32429557.
      Citations: 4     
    19. Mahjabeen S, Hatipoglu MK, Kosanke SD, Garcia-Contreras D, Benbrook DM, Garcia-Contreras L. Vaginal Suppositories Containing SHetA2 to Treat Cervical Dysplasia: Pharmacokinetics of Daily Doses and Preliminary Safety Profile. J Pharm Sci. 2020 06; 109(6):2000-2008. PMID: 32113976.
      Citations: 2     Fields:    Translation:HumansAnimals
    20. Sharma A, Li M, Thavathiru E, Ibrahim M, Garcia-Contreras L, Benbrook DM, Woo S. Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice. AAPS J. 2020 02 21; 22(2):51. PMID: 32086622.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    21. Ramraj SK, Elayapillai SP, Pelikan RC, Zhao YD, Isingizwe ZR, Kennedy AL, Lightfoot SA, Benbrook DM. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53. Int J Cancer. 2020 08 15; 147(4):1086-1097. PMID: 31845320.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    22. Gnanasekaran KK, Pouland T, Bunce RA, Darrell Berlin K, Abuskhuna S, Bhandari D, Mashayekhi M, Zhou DH, Benbrook DM. Tetrahydroquinoline units in flexible heteroarotinoids (Flex-Hets) convey anti-cancer properties in A2780 ovarian cancer cells. Bioorg Med Chem. 2020 01 01; 28(1):115244. PMID: 31831296.
      Citations: 1     Fields:    Translation:HumansCells
    23. Csiszar A, Balasubramanian P, Tarantini S, Yabluchanskiy A, Zhang XA, Springo Z, Benbrook D, Sonntag WE, Ungvari Z. Chemically induced carcinogenesis in rodent models of aging: assessing organismal resilience to genotoxic stressors in geroscience research. Geroscience. 2019 04; 41(2):209-227. PMID: 31037472.
      Citations: 7     Fields:    Translation:HumansAnimals
    24. Nammalwar B, Bunce RA, Berlin KD, Benbrook DM, Toal C. Synthesis and biological evaluation of SHetA2 (NSC-721689) analogs against the ovarian cancer cell line A2780. Eur J Med Chem. 2019 May 15; 170:16-27. PMID: 30878829.
      Citations: 2     Fields:    Translation:HumansCells
    25. Watts FM, Pouland T, Bunce RA, Berlin KD, Benbrook DM, Mashayekhi M, Bhandari D, Zhou D. Activity of oxygen-versus sulfur-containing analogs of the Flex-Het anticancer agent SHetA2. Eur J Med Chem. 2018 Oct 05; 158:720-732. PMID: 30245396.
      Citations: 2     Fields:    Translation:HumansCells
    26. Mahjabeen S, Hatipoglu MK, Benbrook DM, Garcia-Contreras L. Pharmacokinetics and Pharmacodynamics of Escalating Doses of SHetA2 After Vaginal Administration to Mice. J Pharm Sci. 2018 12; 107(12):3179-3186. PMID: 30196041.
      Citations: 3     Fields:    Translation:Animals
    27. Mahjabeen S, Hatipoglu MK, Benbrook DM, Kosanke SD, Garcia-Contreras D, Garcia-Contreras L. Influence of the estrus cycle of the mouse on the disposition of SHetA2 after vaginal administration. Eur J Pharm Biopharm. 2018 Sep; 130:272-280. PMID: 30064701.
      Citations: 4     Fields:    Translation:Animals
    28. Carlson BW, Craft MA, Carlson JR, Razaq W, Deardeuff KK, Benbrook DM. Accelerated vascular aging and persistent cognitive impairment in older female breast cancer survivors. Geroscience. 2018 06; 40(3):325-336. PMID: 29804200.
      Citations: 15     Fields:    Translation:Humans
    29. Sharma A, Benbrook DM, Woo S. Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2. PLoS One. 2018; 13(4):e0194046. PMID: 29634717.
      Citations: 8     Fields:    Translation:Animals
    30. Ramraj SK, Smith KM, Janakiram NB, Toal C, Raman A, Benbrook DM. Correlation of clinical data with fallopian tube specimen immune cells and tissue culture capacity. Tissue Cell. 2018 Jun; 52:57-64. PMID: 29857829.
      Citations: 2     Fields:    Translation:HumansCells
    31. Virani NA, Thavathiru E, McKernan P, Moore K, Benbrook DM, Harrison RG. Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018 07 01; 425:174-182. PMID: 29574275.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    32. Benbrook DM, Janakiram NB, Chandra V, Pathuri G, Madka V, Stratton NC, Masamha CP, Farnsworth CN, Garcia-Contreras L, Hatipoglu MK, Lighfoot S, Rao CV. Development of a dietary formulation of the SHetA2 chemoprevention drug for mice. Invest New Drugs. 2018 08; 36(4):561-570. PMID: 29273857.
      Citations: 6     Fields:    Translation:Animals
    33. Mahjabeen S, Hatipoglu MK, Chandra V, Benbrook DM, Garcia-Contreras L. Optimization of a Vaginal Suppository Formulation to Deliver SHetA2 as a Novel Treatment for Cervical Dysplasia. J Pharm Sci. 2018 02; 107(2):638-646. PMID: 28989018.
      Citations: 7     Fields:    Translation:HumansAnimals
    34. Janakiram NB, Mohammed A, Bryant T, Ritchie R, Stratton N, Jackson L, Lightfoot S, Benbrook DM, Asch AS, Lang ML, Rao CV. Loss of natural killer T cells promotes pancreatic cancer in LSL-KrasG12D/+ mice. Immunology. 2017 09; 152(1):36-51. PMID: 28419443.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    35. Rader JS, Sill MW, Beumer JH, Lankes HA, Benbrook DM, Garcia F, Trimble C, Tate Thigpen J, Lieberman R, Zuna RE, Leath CA, Spirtos NM, Byron J, Thaker PH, Lele S, Alberts D. A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 05; 145(2):291-297. PMID: 28285845.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    36. Griffith J, Andrade D, Mehta M, Berry W, Benbrook DM, Aravindan N, Herman TS, Ramesh R, Munshi A. Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy. Oncol Rep. 2017 Apr; 37(4):2382-2390. PMID: 28260023.
      Citations: 11     Fields:    Translation:HumansCells
    37. Sharma A, Thavathiru E, Benbrook DM, Woo S. Bioanalytical method development and validation of HPLCUV assay for the quantification of SHetA2 in mouse and human plasma: Application to pharmacokinetics study. J Pharm Technol Drug Res. 2017; 6. PMID: 29708233.
      Citations: 4     
    38. Gunderson CC, Ding K, Dvorak J, Moore KN, McMeekin DS, Benbrook DM. The pro-inflammatory effect of obesity on high grade serous ovarian cancer. Gynecol Oncol. 2016 10; 143(1):40-45. PMID: 27423378.
      Citations: 2     Fields:    Translation:Humans
    39. Walgama C, Al Mubarak ZH, Zhang B, Akinwale M, Pathiranage A, Deng J, Berlin KD, Benbrook DM, Krishnan S. Label-Free Real-Time Microarray Imaging of Cancer Protein-Protein Interactions and Their Inhibition by Small Molecules. Anal Chem. 2016 Mar 15; 88(6):3130-5. PMID: 26886845.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    40. Okon IS, Ding Y, Coughlan KA, Wang Q, Song P, Benbrook DM, Zou MH. Aberrant NRP-1 expression serves as predicator of metastatic endometrial and lung cancers. Oncotarget. 2016 Feb 16; 7(7):7970-8. PMID: 26701889.
      Citations: 5     Fields:    Translation:HumansCells
    41. Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016 Jan; 27(1):e8. PMID: 26463434.
      Citations: 41     Fields:    Translation:Humans
    42. Ozpolat B, Benbrook DM. Targeting autophagy in cancer management - strategies and developments. Cancer Manag Res. 2015; 7:291-9. PMID: 26392787.
      Citations: 52     
    43. Gnanasekaran KK, Benbrook DM, Nammalwar B, Thavathiru E, Bunce RA, Berlin KD. Synthesis and evaluation of second generation Flex-Het scaffolds against the human ovarian cancer A2780 cell line. Eur J Med Chem. 2015; 96:209-17. PMID: 25880346.
      Citations: 3     Fields:    Translation:HumansCells
    44. Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK, Jeske Y, Mannel RS, Spillman MA, Lee PS, Hoffman JS, McMeekin DS, Pollock PM. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014 Oct; 135(1):38-43. PMID: 25019571.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    45. Slaughter KN, Thai T, Penaroza S, Benbrook DM, Thavathiru E, Ding K, Nelson T, McMeekin DS, Moore KN. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. Gynecol Oncol. 2014 Apr; 133(1):11-5. PMID: 24680585.
      Citations: 22     Fields:    Translation:Humans
    46. Bishop EA, Lightfoot S, Thavathiru E, Benbrook DM. Insulin exerts direct effects on carcinogenic transformation of human endometrial organotypic cultures. Cancer Invest. 2014 Mar; 32(3):63-70. PMID: 24499106.
      Citations: 5     Fields:    Translation:HumansCells
    47. Benbrook DM, Chambon P, Rochette-Egly C, Asson-Batres MA. History of retinoic acid receptors. Subcell Biochem. 2014; 70:1-20. PMID: 24962878.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    48. Benbrook DM, Nammalwar B, Long A, Matsumoto H, Singh A, Bunce RA, Berlin KD. SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres. Invest New Drugs. 2014 Jun; 32(3):412-23. PMID: 24254390.
      Citations: 20     Fields:    Translation:HumansCells
    49. Benbrook DM, Guruswamy S, Wang Y, Sun Z, Mohammed A, Zhang Y, Li Q, Rao CV. Chemoprevention of colon and small intestinal tumorigenesis in APC(min/+) mice by SHetA2 (NSC721689) without toxicity. Cancer Prev Res (Phila). 2013 Sep; 6(9):908-16. PMID: 23852423.
      Citations: 22     Fields:    Translation:Animals
    50. Moxley KM, Benbrook DM, Queimado L, Zuna RE, Thompson D, McCumber M, Premkumar P, Thavathiru E, Hines L, Moore KN. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer. Gynecol Oncol. 2013 Aug; 130(2):377-82. PMID: 23632208.
      Citations: 7     Fields:    Translation:Humans
    51. Benbrook DM, Long A. Integration of autophagy, proteasomal degradation, unfolded protein response and apoptosis. Exp Oncol. 2012 Oct; 34(3):286-97. PMID: 23070014.
      Citations: 96     Fields:    Translation:HumansCells
    52. Kabirov KK, Kapetanovic IM, Benbrook DM, Dinger N, Mankovskaya I, Zakharov A, Detrisac C, Pereira M, Martín-Jiménez T, Onua E, Banerjee A, van Breemen RB, Nikolic D, Chen L, Lyubimov AV. Oral toxicity and pharmacokinetic studies of SHetA2, a new chemopreventive agent, in rats and dogs. Drug Chem Toxicol. 2013 Jul; 36(3):284-95. PMID: 22947079.
      Citations: 19     Fields:    Translation:Animals
    53. McMeekin DS, Sill MW, Darcy KM, Abulafia O, Hanjani P, Pearl ML, Rubin SC, Rose PG, Small L, Benbrook DM. A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Nov; 127(2):356-61. PMID: 22796461.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    54. Doppalapudi RS, Riccio ES, Davis Z, Menda S, Wang A, Du N, Green C, Kopelovich L, Rao CV, Benbrook DM, Kapetanovic IM. Genotoxicity of the cancer chemopreventive drug candidates CP-31398, SHetA2, and phospho-ibuprofen. Mutat Res. 2012 Jul 04; 746(1):78-88. PMID: 22498038.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    55. Ramachandran I, Thavathiru E, Ramalingam S, Natarajan G, Mills WK, Benbrook DM, Zuna R, Lightfoot S, Reis A, Anant S, Queimado L. Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo. Oncogene. 2012 May 31; 31(22):2725-37. PMID: 22002305.
      Citations: 71     Fields:    Translation:HumansAnimalsCells
    56. Zheng J, Benbrook DM, Yu H, Ding WQ. Clioquinol suppresses cyclin D1 gene expression through transcriptional and post-transcriptional mechanisms. Anticancer Res. 2011 Sep; 31(9):2739-47. PMID: 21868515.
      Citations: 5     Fields:    Translation:HumansCells
    57. Jiang H, Taggart JE, Zhang X, Benbrook DM, Lind SE, Ding WQ. Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline). Cancer Lett. 2011 Dec 15; 312(1):11-7. PMID: 21899946.
      Citations: 40     Fields:    Translation:HumansCells
    58. Dozmorov IM, Jarvis J, Saban R, Benbrook DM, Wakeland E, Aksentijevich I, Ryan J, Chiorazzi N, Guthridge JM, Drewe E, Tighe PJ, Centola M, Lefkovits I. Internal standard-based analysis of microarray data2--analysis of functional associations between HVE-genes. Nucleic Acids Res. 2011 Oct; 39(18):7881-99. PMID: 21715372.
      Citations: 12     Fields:    Translation:Humans
    59. Benbrook DM, Masamha CP. The pro-survival function of Akt kinase can be overridden or altered to contribute to induction of apoptosis. Curr Cancer Drug Targets. 2011 Jun; 11(5):586-99. PMID: 21486222.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    60. Usha L, Sill MW, Darcy KM, Benbrook DM, Hurteau JA, Michelin DP, Mannel RS, Hanjani P, De Geest K, Godwin AK. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol. 2011 Jun 01; 121(3):455-61. PMID: 21414654.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    61. Hurteau JA, Brady MF, Darcy KM, McGuire WP, Edmonds P, Pearl ML, Ivanov I, Tewari KS, Mannel RS, Zanotti K, Benbrook DM. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Dec; 119(3):444-50. PMID: 20846715.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    62. Zheng J, Lou JR, Zhang XX, Benbrook DM, Hanigan MH, Lind SE, Ding WQ. N-Acetylcysteine interacts with copper to generate hydrogen peroxide and selectively induce cancer cell death. Cancer Lett. 2010 Dec 08; 298(2):186-94. PMID: 20667650.
      Citations: 23     Fields:    Translation:HumansCells
    63. Chengedza S, Benbrook DM. NF-kappaB is involved in SHetA2 circumvention of TNF-alpha resistance, but not induction of intrinsic apoptosis. Anticancer Drugs. 2010 Mar; 21(3):297-305. PMID: 20032777.
      Citations: 9     Fields:    Translation:HumansCells
    64. Moxley KM, Chengedza S, Benbrook DM. Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents. Gynecol Oncol. 2009 Dec; 115(3):438-42. PMID: 19804900.
      Citations: 10     Fields:    Translation:HumansCells
    65. Palwai NR, Zang XP, Harrison RG, Benbrook D, Pento JT. Selective growth inhibition of cancer cells by L-methioninase-containing fusion protein targeted to the urokinase receptor. Pharmacology. 2009; 84(5):271-5. PMID: 19797936.
      Citations: 1     Fields:    Translation:HumansCells
    66. Masamha CP, Benbrook DM. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res. 2009 Aug 15; 69(16):6565-72. PMID: 19638577.
      Citations: 92     Fields:    Translation:HumansCells
    67. Tuller ER, Beavers CT, Lou JR, Ihnat MA, Benbrook DM, Ding WQ. Docosahexaenoic acid inhibits superoxide dismutase 1 gene transcription in human cancer cells: the involvement of peroxisome proliferator-activated receptor alpha and hypoxia-inducible factor-2alpha signaling. Mol Pharmacol. 2009 Sep; 76(3):588-95. PMID: 19528198.
      Citations: 19     Fields:    Translation:HumansCells
    68. Liu T, Masamha CP, Chengedza S, Berlin KD, Lightfoot S, He F, Benbrook DM. Development of flexible-heteroarotinoids for kidney cancer. Mol Cancer Ther. 2009 May; 8(5):1227-38. PMID: 19417155.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    69. Tuller ER, Brock AL, Yu H, Lou JR, Benbrook DM, Ding WQ. PPARalpha signaling mediates the synergistic cytotoxicity of clioquinol and docosahexaenoic acid in human cancer cells. Biochem Pharmacol. 2009 May 01; 77(9):1480-6. PMID: 19426685.
      Citations: 11     Fields:    Translation:HumansCells
    70. Liu Z, Zhang Y, Hua YF, Covey JM, Benbrook DM, Chan KK. Metabolism of a sulfur-containing heteroarotionoid antitumor agent, SHetA2, using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008 Nov; 22(21):3371-81. PMID: 18837006.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    71. Lin Y, Liu X, Yue P, Benbrook DM, Berlin KD, Khuri FR, Sun SY. Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells. Mol Cancer Ther. 2008 Nov; 7(11):3556-65. PMID: 19001438.
      Citations: 28     Fields:    Translation:HumansCells
    72. Myers T, Chengedza S, Lightfoot S, Pan Y, Dedmond D, Cole L, Tang Y, Benbrook DM. Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo. Invest New Drugs. 2009 Aug; 27(4):304-18. PMID: 18802666.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    73. Lin YD, Chen S, Yue P, Zou W, Benbrook DM, Liu S, Le TC, Berlin KD, Khuri FR, Sun SY. CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. Cancer Res. 2008 Jul 01; 68(13):5335-44. PMID: 18593935.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    74. Ju T, Lanneau GS, Gautam T, Wang Y, Xia B, Stowell SR, Willard MT, Wang W, Xia JY, Zuna RE, Laszik Z, Benbrook DM, Hanigan MH, Cummings RD. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res. 2008 Mar 15; 68(6):1636-46. PMID: 18339842.
      Citations: 143     Fields:    Translation:HumansCells
    75. Benbrook DM, Lightfoot S, Ranger-Moore J, Liu T, Chengedza S, Berry WL, Dozmorov I. Gene expression analysis of biological systems driving an organotypic model of endometrial carcinogenesis and chemoprevention. Gene Regul Syst Bio. 2008; 2:21-42. PMID: 19784388.
      Citations: 18     
    76. Le TC, Berlin KD, Benson SD, Eastman MA, Bell-Eunice G, Nelson AC, Benbrook DM. Heteroarotinoids with anti-cancer activity against ovarian cancer cells. Open Med Chem J. 2007 Oct 24; 1:11-23. PMID: 19662136.
      Citations: 5     
    77. McMeekin DS, Sill MW, Darcy KM, Stearns-Kurosawa DJ, Webster K, Waggoner S, Benbrook D. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gynecol Oncol. 2007 Sep; 106(3):596-603. PMID: 17597196.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    78. Liu T, Hannafon B, Gill L, Kelly W, Benbrook D. Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria. Mol Cancer Ther. 2007 Jun; 6(6):1814-22. PMID: 17575110.
      Citations: 39     Fields:    Translation:HumansCells
    79. McMeekin DS, Sill MW, Benbrook D, Darcy KM, Stearns-Kurosawa DJ, Eaton L, Yamada SD. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 May; 105(2):508-16. PMID: 17306350.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    80. Benbrook DM. Promise and problems of translational research. Gynecol Oncol. 2006 Nov; 103(2 Suppl 1):S14-7. PMID: 17027066.
      Citations:    Fields:    Translation:Humans
    81. Matsuzaki S, Hayes JM, Benbrook DM, Jankowiak R. Nonphotochemical hole-burning study of selectively stained normal and cancerous human ovarian tissues. J Phys Chem B. 2006 Aug 17; 110(32):16124-30. PMID: 16898770.
      Citations:    Fields:    Translation:Humans
    82. Zhang Y, Hua Y, Benbrook DM, Covey JM, Dai G, Liu Z, Chan KK. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2. Cancer Chemother Pharmacol. 2006 Nov; 58(5):561-9. PMID: 16534614.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    83. Chiu PM, Feng HC, Benbrook DM, Ngan HY, Khoo US, Xue WC, Tsao SW, Chan KW, Cheung AN. Effect of all-trans retinoic acid on tissue dynamics of choriocarcinoma cell lines: an organotypic model. J Clin Pathol. 2006 Aug; 59(8):845-50. PMID: 16461808.
      Citations: 3     Fields:    Translation:HumansCells
    84. Hyde J, Benbrook DM. Sensitivities of Uterine Adenocarcinoma, Mixed Mullerian Tumor (MMT) and Sarcoma Cell Lines to Chemotherapeutic Agents and a Flex-Het Drug. Am J Pharmacol Toxicol. 2006 Jan 01; 1(4):83-86. PMID: 19890461.
      Citations:    
    85. Benbrook DM, Kamelle SA, Guruswamy SB, Lightfoot SA, Rutledge TL, Gould NS, Hannafon BN, Dunn ST, Berlin KD. Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists. Invest New Drugs. 2005 Oct; 23(5):417-28. PMID: 16133793.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    86. Tillmanns TD, Kamelle SA, Guruswamy S, Gould NS, Rutledge TL, Benbrook DM. Sensitization of cervical cancer cell lines to low-dose radiation by retinoic acid does not require functional p53. Gynecol Oncol. 2005 Apr; 97(1):142-50. PMID: 15790450.
      Citations: 3     Fields:    Translation:HumansCells
    87. Liu S, Brown CW, Berlin KD, Dhar A, Guruswamy S, Brown D, Gardner GJ, Birrer MJ, Benbrook DM. Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells. J Med Chem. 2004 Feb 12; 47(4):999-1007. PMID: 14761202.
      Citations: 24     Fields:    Translation:HumansCells
    88. Brown CW, Liu S, Klucik J, Berlin KD, Brennan PJ, Kaur D, Benbrook DM. Novel heteroarotinoids as potential antagonists of Mycobacterium bovis BCG. J Med Chem. 2004 Feb 12; 47(4):1008-17. PMID: 14761203.
      Citations: 6     Fields:    Translation:Cells
    89. Chun KH, Benbrook DM, Berlin KD, Hong WK, Lotan R. The synthetic heteroarotinoid SHetA2 induces apoptosis in squamous carcinoma cells through a receptor-independent and mitochondria-dependent pathway. Cancer Res. 2003 Jul 01; 63(13):3826-32. PMID: 12839980.
      Citations: 14     Fields:    Translation:HumansCells
    90. Mic FA, Molotkov A, Benbrook DM, Duester G. Retinoid activation of retinoic acid receptor but not retinoid X receptor is sufficient to rescue lethal defect in retinoic acid synthesis. Proc Natl Acad Sci U S A. 2003 Jun 10; 100(12):7135-40. PMID: 12782789.
      Citations: 101     Fields:    Translation:AnimalsCells
    91. Hassan R, Lerner MR, Benbrook D, Lightfoot SA, Brackett DJ, Wang QC, Pastan I. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res. 2002 Nov; 8(11):3520-6. PMID: 12429643.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    92. Kamelle S, Sienko A, Benbrook DM. Retinoids and steroids regulate menstrual phase histological features in human endometrial organotypic cultures. Fertil Steril. 2002 Sep; 78(3):596-602. PMID: 12215339.
      Citations: 11     Fields:    Translation:HumansCells
    93. Benbrook DM. Refining retinoids with heteroatoms. Mini Rev Med Chem. 2002 Jun; 2(3):277-83. PMID: 12370069.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    94. Benbrook DM. An ELISA method for detection of human antibodies to an immunotoxin. J Pharmacol Toxicol Methods. 2002 May-Jun; 47(3):169-75. PMID: 12628308.
      Citations: 2     Fields:    Translation:HumansAnimals
    95. Scribner DR, Benbrook DM. Retinoids enhance cisplatin-based chemoradiation in cervical cancer cells in vitro. Gynecol Oncol. 2002 Apr; 85(1):223-5. PMID: 11925151.
      Citations: 4     Fields:    Translation:HumansCells
    96. Simoni D, Roberti M, Invidiata FP, Rondanin R, Baruchello R, Malagutti C, Mazzali A, Rossi M, Grimaudo S, Capone F, Dusonchet L, Meli M, Raimondi MV, Landino M, D'Alessandro N, Tolomeo M, Arindam D, Lu S, Benbrook DM. Heterocycle-containing retinoids. Discovery of a novel isoxazole arotinoid possessing potent apoptotic activity in multidrug and drug-induced apoptosis-resistant cells. J Med Chem. 2001 Jul 05; 44(14):2308-18. PMID: 11428925.
      Citations: 5     Fields:    Translation:HumansCells
    97. Guruswamy S, Lightfoot S, Gold MA, Hassan R, Berlin KD, Ivey RT, Benbrook DM. Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma. J Natl Cancer Inst. 2001 Apr 04; 93(7):516-25. PMID: 11287445.
      Citations: 20     Fields:    Translation:HumansCells
    98. Zacheis D, Dhar A, Lu S, Madler MM, Klucik J, Brown CW, Liu S, Clement F, Subramanian S, Weerasekare GM, Berlin KD, Gold MA, Houck JR, Fountain KR, Benbrook DM. Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors. J Med Chem. 1999 Oct 21; 42(21):4434-45. PMID: 10543887.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    99. Dhar A, Liu S, Klucik J, Berlin KD, Madler MM, Lu S, Ivey RT, Zacheis D, Brown CW, Nelson EC, Birckbichler PJ, Benbrook DM. Synthesis, structure-activity relationships, and RARgamma-ligand interactions of nitrogen heteroarotinoids. J Med Chem. 1999 Sep 09; 42(18):3602-14. PMID: 10479291.
      Citations: 7     Fields:    Translation:HumansCells
    100. Salsman S, Lu S, Benbrook DM. The mechanism of retinoic acid radiosensitization is independent of AP-1 repression in a cervical carcinoma cell line. Gynecol Oncol. 1999 May; 73(2):253-6. PMID: 10329043.
      Citations: 1     Fields:    Translation:HumansCells
    101. DiSilvestro PA, Lightfoot SA, Benbrook DM. Ki-67 Expression in a Cervical Cancer Organotypic Model Correlates with Growth and EGF-R Expression. J Low Genit Tract Dis. 1999 Apr; 3(2):111-5. PMID: 25950557.
      Citations:    Fields:    
    102. Waliszewski P, Waliszewska M, Gordon N, Hurst RE, Benbrook DM, Dhar A, Hemstreet GP. Retinoid signaling in immortalized and carcinoma-derived human uroepithelial cells. Mol Cell Endocrinol. 1999 Feb 25; 148(1-2):55-65. PMID: 10221771.
      Citations: 2     Fields:    Translation:HumansCells
    103. Hurst RE, Waliszewski P, Waliszewska M, Bonner RB, Benbrook DM, Dar A, Hemstreet GP. Complexity, retinoid-responsive gene networks, and bladder carcinogenesis. Adv Exp Med Biol. 1999; 462:449-67. PMID: 10599447.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    104. Benbrook DM, Subramanian S, Gale JB, Liu S, Brown CW, Boehm MF, Berlin KD. Synthesis and characterization of heteroarotinoids demonstrate structure specificity relationships. J Med Chem. 1998 Sep 10; 41(19):3753-7. PMID: 9733501.
      Citations: 7     Fields:    Translation:AnimalsCells
    105. Benbrook DM, Madler MM, Spruce LW, Birckbichler PJ, Nelson EC, Subramanian S, Weerasekare GM, Gale JB, Patterson MK, Wang B, Wang W, Lu S, Rowland TC, DiSivestro P, Lindamood C, Hill DL, Berlin KD. Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity. J Med Chem. 1997 Oct 24; 40(22):3567-83. PMID: 9357524.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    106. Miller AM, Sahl WJ, Brown SA, Young SK, Quinlan CM, Patel PR, Benbrook DM, Naylor MF. The role of human papillomavirus in the development of pyogenic granulomas. Int J Dermatol. 1997 Sep; 36(9):673-6. PMID: 9352408.
      Citations:    Fields:    Translation:HumansCells
    107. Benbrook DM, Lu S, Flanagan C, Shen-Gunther J, Angros LH, Lightfoot SA. Biological assay for activity and molecular mechanism of retinoids in cervical tumor cells. Gynecol Oncol. 1997 Jul; 66(1):114-21. PMID: 9234931.
      Citations: 4     Fields:    Translation:HumansCells
    108. Johnson GA, Mannel R, Khalifa M, Walker JL, Wren M, Min KW, Benbrook DM. Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival. Gynecol Oncol. 1997 Jun; 65(3):425-9. PMID: 9190969.
      Citations: 14     Fields:    Translation:Humans
    109. Benbrook DM, Shen-Gunther J, Nuñez ER, Dynlacht JR. Differential retinoic acid radiosensitization of cervical carcinoma cell lines. Clin Cancer Res. 1997 Jun; 3(6):939-45. PMID: 9815769.
      Citations: 2     Fields:    Translation:HumansCells
    110. Benbrook DM, Rogers RS, Medlin MA, Dunn ST. Immunohistochemical analysis of proliferation and differentiation in organotypic cultures of cervical tumor cell lines. Tissue Cell. 1995 Jun; 27(3):269-74. PMID: 7645007.
      Citations: 2     Fields:    Translation:HumansCells
    111. Apfel R, Benbrook D, Lernhardt E, Ortiz MA, Salbert G, Pfahl M. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol Cell Biol. 1994 Oct; 14(10):7025-35. PMID: 7935418.
      Citations: 104     Fields:    Translation:AnimalsCells
    112. Benbrook DM, Jones NC. Different binding specificities and transactivation of variant CRE's by CREB complexes. Nucleic Acids Res. 1994 Apr 25; 22(8):1463-9. PMID: 8190638.
      Citations: 37     Fields:    Translation:HumansCells
    113. Benbrook DM, Jones NC. Heterodimer formation between CREB and JUN proteins. Oncogene. 1990 Mar; 5(3):295-302. PMID: 2138276.
      Citations: 108     Fields:    Translation:HumansCells
    114. Benbrook D, Lernhardt E, Pfahl M. A new retinoic acid receptor identified from a hepatocellular carcinoma. Nature. 1988 Jun 16; 333(6174):669-72. PMID: 2836738.
      Citations: 103     Fields:    Translation:HumansCells
    115. Pfahl M, Benbrook D. Nucleotide sequence of cDNA encoding a novel human thyroid hormone receptor. Nucleic Acids Res. 1987 Nov 25; 15(22):9613. PMID: 3684612.
      Citations: 3     Fields:    Translation:HumansCells
    116. Benbrook D, Pfahl M. A novel thyroid hormone receptor encoded by a cDNA clone from a human testis library. Science. 1987 Nov 06; 238(4828):788-91. PMID: 3672126.
      Citations: 45     Fields:    Translation:HumansCells
    117. Benbrook DM, Miller RV. Effects of norfloxacin on DNA metabolism in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1986 Jan; 29(1):1-6. PMID: 3015000.
      Citations: 29     Fields:    Translation:Cells
    Benbrook's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (544)
    Explore
    _
    Co-Authors (50)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _